Anagrelide controlled release - AOP Orphan Pharmaceuticals

Drug Profile

Anagrelide controlled release - AOP Orphan Pharmaceuticals

Alternative Names: Anagrelide CR; Anagrelide retard; ANAT2; Anathromb

Latest Information Update: 06 Jun 2016

Price : $50

At a glance

  • Originator AOP Orphan Pharmaceuticals AG
  • Class 3-ring heterocyclic compounds; Antiplatelets; Imidazoles; Quinazolines; Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Essential thrombocythaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2015 AOP Orphan completes a phase III TEAM-ET trial for Essential thrombocythaemia in Austria and Lithuania (NCT02076815)
  • 30 Jan 2015 AOP Orphan completes a phase-III trial for Essential thrombocytopenia in Austria, Bulgaria, Croatia, Hungary, Lithuania, Poland, Romania, Russia, Slovakia, Slovenia and Ukraine (PO) (NCT01230775)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top